These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28318628)

  • 1. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
    Rosenzwajg M; Languille E; Debiec H; Hygino J; Dahan K; Simon T; Klatzmann D; Ronco P
    Kidney Int; 2017 Jul; 92(1):227-237. PubMed ID: 28318628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab increases peripheral natural killer cells in patients with rheumatoid arthritis.
    Giollo A; Viapiana O; Carletto A; Ortolani R; Biasi D; Gatti D; Adami S; Rossini M
    Clin Exp Rheumatol; 2017; 35(2):241-246. PubMed ID: 27908302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology.
    Sentís A; Diekmann F; Llobell A; de Moner N; Espinosa G; Yagüe J; Campistol JM; Mirapeix E; Juan M
    Immunobiology; 2017 Apr; 222(4):620-630. PubMed ID: 27986304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion.
    Herrera Lara S; Fernández-Fabrellas E; Juan Samper G; Marco Buades J; Andreu Lapiedra R; Pinilla Moreno A; Morales Suárez-Varela M
    Lung; 2019 Feb; 197(1):53-60. PubMed ID: 30523401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between High NK-Cell Count and Remission of Primary Membranous Nephropathy: A Retrospective Chart Review and Pilot Study.
    Chen W; Cai J; Raffetseder U; Zhu B; Chen J; Song N; Li Y; Lu Y; Fang Y; Ding X; Wang J
    Clin Ther; 2023 Apr; 45(4):364-374. PubMed ID: 36997447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
    Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy.
    Zhang Y; Yang J; Li J; Sun J; Zhou L; Xu D; Sha W; Dai L; Shen L
    BMC Nephrol; 2024 Mar; 25(1):86. PubMed ID: 38448810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
    Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
    J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia.
    Gudbrandsdottir S; Brimnes M; Køllgaard T; Hasselbalch HC; Nielsen CH
    Eur J Haematol; 2018 Jan; 100(1):45-52. PubMed ID: 28960473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.
    Lee SK; Kim JY; Jang BW; Hur SE; Na BJ; Lee M; Fukui A; Gilman-Sachs A; Kwak-Kim J
    Hum Immunol; 2011 Aug; 72(8):621-6. PubMed ID: 21600259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
    Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
    BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.
    Ghosh S; Nandi M; Pal S; Mukhopadhyay D; Chakraborty BC; Khatun M; Bhowmick D; Mondal RK; Das S; Das K; Ghosh R; Banerjee S; Santra A; Chatterjee M; Chowdhury A; Datta S
    Clin Microbiol Infect; 2016 Aug; 22(8):733.e9-733.e19. PubMed ID: 27208430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status.
    Chalan P; Bijzet J; Kroesen BJ; Boots AM; Brouwer E
    J Rheumatol; 2016 Jun; 43(6):1008-16. PubMed ID: 27036380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in CD16/CD56 and CD16/CD3/CD56 Natural Killer Cells in Coronary Artery Disease.
    Jabir NR; Firoz CK; Ahmed F; Kamal MA; Hindawi S; Damanhouri GA; Almehdar HA; Tabrez S
    Immunol Invest; 2017 Jul; 46(5):526-535. PubMed ID: 28414590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
    Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Membranous Nephropathy after MENTOR.
    Trivin-Avillach C; Beck LH
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):415-417. PubMed ID: 31740571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.